Augmenting Endothelial Repair in Diabetes: Role of Bone Marrow-Derived Cells

Canadian Journal of Diabetes

Volumn 37, Issue 5, 2013, Pages 315-318

  Gilbert, Richard E ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Bone marrow; Coronary artery disease; Endothelial progenitor cells; Endothelium; Nephropathy; Retinopathy

Indexed keywords

ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV; EZETIMIBE; GRANULOCYTE COLONY STIMULATING FACTOR; JVS 100; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NITRIC OXIDE; PARVOVIRUS VECTOR; RENIN INHIBITOR; SILENT INFORMATION REGULATOR PROTEIN; SILENT INFORMATION REGULATOR PROTEIN 1; SITAGLIPTIN; STROMAL CELL DERIVED FACTOR 1ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2;

ACUTE HEART INFARCTION; ADD ON THERAPY; ANGIOGENESIS; APOPTOSIS; CARDIOVASCULAR DISEASE; CELL COUNT; CELL FUNCTION; CELL LOSS; CELL MIGRATION; CELL PROLIFERATION; CELL REGENERATION; CLINICAL TRIAL (TOPIC); CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DIABETIC MICROANGIOPATHY; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; DRUG DOSE ESCALATION; ENDOTHELIAL DYSFUNCTION; ENDOTHELIAL PROGENITOR CELL; ENDOTHELIAL REPAIR; ENDOTHELIUM CELL; GLYCEMIC CONTROL; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; KIDNEY FAILURE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOGENESIS; REVIEW; TISSUE REPAIR; BIOLOGICAL THERAPY; BONE MARROW CELL; COMPLICATION; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FEMALE; MALE; PATHOPHYSIOLOGY; STEM CELL TRANSPLANTATION; TRANSPLANTATION; TREATMENT OUTCOME; VASCULAR ENDOTHELIUM;

BONE MARROW CELLS; CELL PROLIFERATION; CELL- AND TISSUE-BASED THERAPY; CORONARY ARTERY DISEASE; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; MALE; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84884694538     PISSN: 14992671     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcjd.2013.06.009     Document Type: Review

References (46)

1. Ross R., Glomset J.A. Atherosclerosis and the arterial smooth muscle cell: proliferation of smooth muscle is a key event in the genesis of the lesions of atherosclerosis. Science 1973, 180:1332-1339.
2. Asahara T., Murohara T., Sullivan A., et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997, 275:964-967.
3. Yoder M.C. Human endothelial progenitor cells. Cold Spring Harb Perspect Med 2012, 2:a006692.
4. Jaumdally R.J., Goon P.K., Varma C., et al. Effects of atorvastatin on circulating CD34+/CD133+/ CD45- progenitor cells and indices of angiogenesis (vascular endothelial growth factor and the angiopoietins 1 and 2) in atherosclerotic vascular disease and diabetes mellitus. JIntern Med 2010, 267:385-393.
5. Schmidt-Lucke C., Fichtlscherer S., Rossig L., et al. Improvement of endothelial damage and regeneration indexes in patients with coronary artery disease after 4 weeks of statin therapy. Atherosclerosis 2010, 211:249-254.
6. Mohler E.R., Shi Y., Moore J., et al. Diabetes reduces bone marrow and circulating porcine endothelial progenitor cells, an effect ameliorated by atorvastatin and independent of cholesterol. Cytometry Part A 2009, 75A:75-82.
7. Durik M., Seva Pessoa B., Roks A.J. The renin-angiotensin system, bone marrow and progenitor cells. Clin Sci (Lond) 2012, 123:205-223.
8. Endtmann C., Ebrahimian T., Czech T., et al. Angiotensin II impairs endothelial progenitor cell number and function invitro and invivo: implications for vascular regeneration. Hypertension 2011, 58:394-403.
9. Thum T., Fraccarollo D., Galuppo P., et al. Bone marrow molecular alterations after myocardial infarction: impact on endothelial progenitor cells. Cardiovasc Res 2006, 70:50-60.
10. Yu Y., Wang Y., Zhou L.N., et al. ARB treatment prevents the decrease in endothelial progenitor cells and the loss of renal microvasculature in remnant kidney. Am J Nephrol 2011, 33:550-557.
11. Wang C.H., Verma S., Hsieh I.C., et al. Enalapril increases ischemia-induced endothelial progenitor cell mobilization through manipulation of the CD26 system. JMol Cell Cardiol 2006, 41:34-43.
12. Porto I., Di Vito L., De Maria G.L., et al. Comparison of the effects of ramipril versus telmisartan on high-sensitivity C-reactive protein and endothelial progenitor cells after acute coronary syndrome. Am J Cardiol 2009, 103:1500-1505.
13. Tipnis S.R., Hooper N.M., Hyde R., et al. Ahuman homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. JBiol Chem 2000, 275:33238-33243.
14. Donoghue M., Hsieh F., Baronas E., et al. Anovel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. CircRes 2000, 87:E1-E9.
15. Ingelfinger J.R. Angiotensin-converting enzyme 2: implications for blood pressure and kidney disease. Curr Opin Nephrol Hypertens 2009, 18:79-84.
16. Sampaio W.O., Souza dos Santos R.A., Faria-Silva R., et al. Angiotensin-(1-7) through receptor Mas mediates endothelial nitric oxide synthase activation via Akt-dependent pathways. Hypertension 2007, 49:185-192.
17. Benter I.F., Yousif M.H., Dhaunsi G.S., et al. Angiotensin-(1-7) prevents activation of NADPH oxidase and renal vascular dysfunction in diabetic hypertensive rats. Am J Nephrol 2008, 28:25-33.
18. Oudit G.Y., Liu G.C., Zhong J., et al. Human recombinant ACE2 reduces the progression of diabetic nephropathy. Diabetes 2010, 59:529-538.
19. Verma A., Shan Z., Lei B., et al. ACE2 and Ang-(1-7) confer protection against development of diabetic retinopathy. Mol Ther 2012, 20:28-36.
20. Jarajapu Y.P., Bhatwadekar A.D., Caballero S., et al. Activation of the ACE2/angiotensin-(1-7)/Mas receptor axis enhances the reparative function of dysfunctional diabetic endothelial progenitors. Diabetes 2013, 62:1258-1269.
21. Takahashi M. Role of the SDF-1/CXCR4 system in myocardial infarction. Circ J 2010, 74:418-423.
22. Askari A.T., Unzek S., Popovic Z.B., et al. Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy. Lancet 2003, 362:697-703.
23. Segers V.F., Tokunou T., Higgins L.J., et al. Local delivery of protease-resistant stromal cell derived factor-1 for stem cell recruitment after myocardial infarction. Circulation 2007, 116:1683-1692.
24. Proost P., Struyf S., Schols D., et al. Processing by CD26/dipeptidyl-peptidase IV reduces the chemotactic and anti-HIV-1 activity of stromal-cell-derived factor-1alpha. FEBS Lett 1998, 432:73-76.
25. Zaruba M.M., Theiss H.D., Vallaster M., et al. Synergy between CD26/DPP-IV inhibition and G-CSF improves cardiac function after acute myocardial infarction. Cell Stem Cell 2009, 4:313-323.
26. Shigeta T., Aoyama M., Bando Y.K., et al. Dipeptidyl peptidase-4 modulates left ventricular dysfunction in chronic heart failure via angiogenesis-dependent and -independent actions. Circulation 2012, 126:1838-1851.
27. Connelly K., Zhang Y., Advani A., et al. DPP-4 inhibition attenuates cardiac dysfunction and adverse remodelling following myocardial infarction in rats with experimental diabetes. Cardiovasc Ther 2012, Epub ahead of print.
28. Fadini G.P., Boscaro E., Albiero M., et al. The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha. Diabetes Care 2010, 33:1607-1609.
29. Fadini G.P., Boscaro E., de Kreutzenberg S., et al. Time course and mechanisms of circulating progenitor cell reduction in the natural history of type 2 diabetes. Diabetes Care 2010, 33:1097-1102.
30. Fadini G.P., Miorin M., Facco M., et al. Circulating endothelial progenitor cells are reduced in peripheral vascular complications of type 2 diabetes mellitus. JAm Coll Cardiol 2005, 45:1449-1457.
31. Egan C.G., Lavery R., Caporali F., et al. Generalised reduction of putative endothelial progenitors and CXCR4-positive peripheral blood cells in type 2 diabetes. Diabetologia 2008, 51:1296-1305.
32. Kusuyama T., Omura T., Nishiya D., et al. Effects of treatment for diabetes mellitus on circulating vascular progenitor cells. JPharmacol Sci 2006, 102:96-102.
33. Jarajapu Y.P., Grant M.B. The promise of cell-based therapies for diabetic complications: challenges and solutions. Circ Res 2010, 106:854-869.
34. Hamed S., Brenner B., Roguin A. Nitric oxide: a key factor behind the dysfunctionality of endothelial progenitor cells in diabetes mellitus type-2. Cardiovasc Res 2011, 91:9-15.
35. Hamed S., Brenner B., Aharon A., et al. Nitric oxide and superoxide dismutase modulate endothelial progenitor cell function in type 2 diabetes mellitus. Cardiovasc Diabetol 2009, 8:56.
36. Segal M.S., Shah R., Afzal A., et al. Nitric oxide cytoskeletal-induced alterations reverse the endothelial progenitor cell migratory defect associated with diabetes. Diabetes 2006, 55:102-109.
37. Yuen D.A., Zhang Y., Thai K., et al. Angiogenic dysfunction in bone marrow-derived early outgrowth cells from diabetic animals is attenuated by SIRT1 activation. Stem Cells Transl Med 2012, 1:921-926.
38. Asada T., Ogawa T., Iwai M., et al. Recombinant insulin-like growth factor I normalizes expression of renal glucose transporters in diabetic rats. Am J Physiol 1997, 273:F27-F37.
39. Limbourg F.P., Drexler H. Bone marrow stem cells for myocardial infarction: effector or mediator?. Circ Res 2005, 96:6-8.
40. Gnecchi M., Zhang Z., Ni A., et al. Paracrine mechanisms in adult stem cell signaling and therapy. Circ Res 2008, 103:1204-1219.
41. Yuen D.A., Connelly K.A., Advani A., et al. Culture-modified bone marrow cells attenuate cardiac and renal injury in a chronic kidney disease rat model via a novel antifibrotic mechanism. PLoS One 2010, 5:e9543.
42. Bi B., Schmitt R., Israilova M., et al. Stromal cells protect against acute tubular injury via an endocrine effect. JAm Soc Nephrol 2007, 18:2486-2496.
43. Prockop D.J. Repair of tissues by adult stem/progenitor cells (MSCs): controversies, myths, and changing paradigms. Mol Ther 2009, 17:939-946.
44. Zhang Y., Yuen D.A., Advani A., et al. Early-outgrowth bone marrow cells attenuate renal injury and dysfunction via an antioxidant effect in a mouse model of type 2 diabetes. Diabetes 2012, 61:2114-2125.
45. Gilbert R.E. Endothelial loss and repair in the vascular complications of diabetes: pathogenetic mechanisms and therapeutic implications. Circ J 2013, 77:849-856.
46. Hare J.M., Traverse J.H., Henry T.D., et al. Arandomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. JAm Coll Cardiol 2009, 54:2277-2286.